Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Defining the cardiac acetylome in type 2 diabetes

ABSTRACT: Here, we aimed to assess the effect of type 2 diabetes on lysine acetylation levels of cardiac muscles. We used human left ventricular samples from human donors with and without diabetes and investigated the acetylome.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cardiac Muscle

SUBMITTER: Michael Wierer

LAB HEAD: Julien Ochala

PROVIDER: PXD068671 | Pride | 2026-03-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20250523_ASC2_EVO1_Zoom20_P413_R1531_X2859_DIA_E00000403_Global_A1.raw	Raw
	20250523_ASC2_EVO1_Zoom20_P413_R1531_X2859_DIA_E00000403_Global_A10.raw	Raw
	20250523_ASC2_EVO1_Zoom20_P413_R1531_X2859_DIA_E00000403_Global_A11.raw	Raw
	20250523_ASC2_EVO1_Zoom20_P413_R1531_X2859_DIA_E00000403_Global_A12.raw	Raw
	20250523_ASC2_EVO1_Zoom20_P413_R1531_X2859_DIA_E00000403_Global_A13.raw	Raw

Items per page:

1 - 5 of 51

Publications

Destabilization of cardiac myosin acetylation and sequestration with type 2 diabetes mellitus.

Degezelle Mahault Mathilde MM Chaami Chahida C Lewis Christopher T A CTA Zhang Chengxin C Hessel Anthony L AL Rainer Peter P PP Kirk Jonathan A JA Stokke Mathis Korseberg MK Seaborne Robert A E RAE Ochala Julien J

Cardiovascular diabetology 20260116

<h4>Background</h4>Type 2 diabetes mellitus (T2DM) predisposes patients to adverse cardiac remodeling even before the development of cardiomyopathic symptoms. The mechanisms for such early perturbations remain elusive. Given that myosin is the most abundant and energy‑demanding cardiac protein, we tested whether its regulation is impaired even in non‑failing human diabetic hearts.<h4>Methods</h4>Left ventricular strips were individually isolated from organ donors with and without T2DM. These str ...[more]

PMID: 41546080

Similar Datasets

Proteomics Reveals Altered Lipid Biosynthesis and Keratin Hyperphosphorylation in Pachyonychia Congenita

Project description:Pachyonychia congenita (PC) is a rare and painful skin disorder caused by dominant mutations in keratin genes (KRT6A/KRT6B/KRT6C/KRT16/KRT17), with no effective treatment. We developed a scalable, in-depth and miniaturized MS-based proteomics and phospho-proteomics analysis of full-thickness skin biopsies applied to 10 PC patients to elucidate pathogenic mechanisms and pinpoint new therapeutic targets. We could quantify 7200 Protein Groups (PGs), on average from 2mm snap-frozen skin samples, the most in-depth proteome coverage reported to date in a single-shot MS analysis. Among the identified PGs, ~1400 proteins were significantly deregulated in lesional vs. non-lesional samples. Enrichment analysis points to impaired mitochondrial function, hyper-keratinization, enhanced immune response and a significant increase in cholesterol biosynthesis pathway. Phosphoproteomics study revealed hyper-phosphorylation of specific sites in PC-related keratins. It confirmed the activation of EGFR downstream kinases, including PKC and Src, and disclosed p38 MAPK activation, which have been reported to phosphorylate keratins. Our work expands the understanding of the consequences of EGFR pathway activation, including mTOR-dependent increase in cholesterol biosynthesis, thereby renewing interest in the use of statins for PC. Above all, it provides a solid foundation for the continued exploration of EGFR inhibitors and offers new therapeutic avenues, particularly those using multikinase inhibitors.

2026-01-14 | PXD067480 | Pride

Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment

Project description:Human genome-wide association studies (GWAS) suggest a functional role for central glutamate receptor signaling and plasticity in body weight regulation. Here, we utilize UK Biobank GWAS summary statistics of body mass index (BMI) and body fat percentage (BF%) to identify genes encoding for proteins known to interact with postsynaptic AMPA and NMDA receptors. Loci in/near Discs Large Homolog 4 (DLG4) and protein interacting with C kinase 1 (PICK1) reached genome-wide significance (P<5x10-8) for BF% and/or BMI. To further evaluate the functional role of PSD-95 (gene name: DLG4) and PICK1 in energy homeostasis, we used dimeric PDZ-domain-targeting peptides of PSD-95 and PICK1 to demonstrate that pharmacological inhibition of PSD-95 and PICK1 induces prolonged weight-lowering effects in obese mice. Collectively, these data demonstrate that the glutamate receptor scaffolding proteins, PICK1 and PSD-95, are genetically linked to obesity and that pharmacological targeting of their PDZ domains represents a promising new therapeutic avenue for sustained weight loss.

2024-06-16 | PXD047515 | Pride

GRK-biased adrenergic agonists for the treatment of type II diabetes and obesity

Project description:Biased agonism of G protein-coupled receptors (GPCRs) holds great promise for the development of safer medications. Current efforts have explored the balance between heterotrimeric G proteins and the scaffold protein b-arrestin; however, other transducers like GPCR kinases (GRKs) represent important, but understudied mediators of agonist-induced signaling. In particular, GRK2 has been shown to play an essential role in b2 adrenergic receptor (b2AR)-mediated glucose uptake, but b2AR agonists are generally thought to make poor clinical candidates for glycemic management given their potential for Gs/cAMP-induced cardiac side effects and tendency for b-arrestin-dependent desensitization with long-term treatment. For these reasons, we sought to develop pathway-selective agonists of b2AR that prefer GRK coupling to heterotrimeric Gs and b-arrestin. Ligand-based virtual screening and chemical evolution of adrenergic agonists led to the identification of GRK-biased b2AR partial agonists. We demonstrate that these compounds perform well in preclinical models of hyperglycemia and obesity and demonstrate a lower potential for cardiac and muscular side effects compared to standard b2-receptor agonists and incretin mimetics respectively. Furthermore, our lead candidate showed favorable pharmacokinetics and was determined to be safe in a placebo-controlled clinical trial. GRK-biased b2AR partial agonists are thus promising candidates to offer a viable, orally available alternative to injection-based incretin mimetics used in the treatment of type II diabetes and obesity.

2025-05-05 | PXD058545 | Pride

SARS-CoV-2 variants evolve convergent strategies to remodel the host response: Infection proteomics

Project description:We sought to compare differences in the human cellular response to distinct SARS-CoV-2 variants of concern. Here, we infected Calu-3 lung epithelial cells with each of the SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta, and Omicron) compared to two early-lineage controls (VIC and IC19). We performed global abundance proteomics and phosphoproteomics at 10, 24, and, for certain samples, 48 hours post infection to comprehensively characterize the host response to infection.

2024-02-16 | PXD036968 | Pride

Global proteomics reveals distinct muscle adaptations to menstrual cycle phase-based sprint interval training in endurance-trained females

Project description:Advances in mass-spectrometry (MS)-based technologies have leveraged our understanding of protein-wide adaptations in human skeletal muscle in response to exercise. However, there is a lack of such data in females, particularly pertaining to already trained females and menstrual cycle phase-based sprint interval training (SIT) despite its efficacy and popularity. Here, we present a comprehensive global proteome analysis of skeletal muscle adaptations to high-frequency SIT during different menstrual cycle phases in endurance-trained females. We randomized 49 eumenorrheic females to either high-frequency SIT in the follicular (FB) or luteal phase (LB) over one menstrual cycle comprising eight sessions of 6×30-s all-out efforts. MS-proteomics, covering 4155 proteins after filtering, revealed notable differences in muscle adaptations to phase-based SIT. LB suppressed mitochondrial pathways of the tricarboxylic acid cycle and electron transport chain while enriching ribosomal complexes. Conversely, FB enriched filament organization and skeletal system development. Mitochondrial repression during LB was linked to reduced O2max, whereas exercise capacity improved in FB only. Our findings show that menstrual cycle phase-based high-frequency SIT induces distinct protein-wide muscle adaptations and affects phenotype in endurance-trained eumenorrheic females.

2025-08-21 | PXD051852 | Pride

HIF-2a drives hepatic Kupffer cell death and liver inflammation in nonalcoholic steatohepatitis

Project description:Proinflammatory activation of hepatic macrophages plays a key role in the development of nonalcoholic steatohepatitis (NASH). This involves increased embryonic hepatic Kupffer cell (KC) death, facilitating the placement of KCs with bone marrow-derived recruited hepatic macrophages (RHMs) that highly express proinflammatory genes. Moreover, phago/efferocytic activity of KCs is diminished in NASH, enhancing liver inflammation. However, the molecular mechanisms underlying these changes in KCs are not known. Here, we show that HIF-2a mediates NASH-associated decreased KC growth and efferocytosis by enhancing lysosomal stress. At the molecular level, HIF-2a stimulated mTOR and ERK-dependent inhibitory TFEB phosphorylation, leading to decreased lysosomal and phagocytic gene expression. With increased metabolic stress and phago/efferocytic burden in NASH, these changes were sufficient to increase lysosomal stress, causing decreased efferocytosis and lysosomal cell death. Of interest, HIF-2a-dependent TFEB regulation only occurred in KCs, but not in RHMs. Instead, in RHMs, HIF-2a promoted mtROS production and proinflammatory activation by increasing ANT2 expression and mitochondrial permeability transition. Taken together, our results suggest that macrophage subtype-specific effects of HIF-2a collectively contributes to the proinflammatory activation of liver macrophages, leading to the development of NASH.

2025-05-06 | PXD040457 | Pride

Covalent fragment screening to inhibit the E3 ligase activity of bacterial NEL enzymes SspH1 and SspH2

Project description:As the global fight against antimicrobial resistance in bacteria becomes increasingly pressing, new tool compounds are needed to understand and identify novel therapeutic targets. Here, cysteine-directed fragment-based drug discovery is coupled with a high throughput chemistry direct-to-biology screening platform to target the catalytic cysteine of a family of bacterial effector proteins, the Novel E3 Ligases (NELs) from Salmonella and Shigella. These effector E3 ligases are particularly interesting as a potential drug target because they are injected into host cells during infection, have no human homologues and disrupt host immune response to infection. We successfully identify lead compounds against the SspH subfamily of NELs from Salmonella and show that these proteins are inhibited by compound treatment, representing an exciting starting point for development into specific and potent tool compounds.

2025-11-10 | PXD057304 | Pride

The histone modifier KANSL2 is an actionable biomarker for response to epigenetic modifiers in multiple myeloma

Project description:Epigenetic aberrations are key drivers of multiple myeloma (MM), yet targeted therapies exploiting epigenetic alterations have not been established. By integrating clinical and molecular MM patient data sets with an unbiased genetic in vivoscreen, we identified KAT8 regulatory NSL complex subunit 2 (KANSL2) as a histone posttranslational modification (PTM)-associated candidate oncogene. High expression of KANSL2 was associated with adverse prognosis in MM patients. Genetic gain and loss of function models identified a protective role of KANSL2 towards genotoxic stress. By transcriptomics, proteomics and quantitative acetylome profiling, we identified a KANSL2-dependent specific molecular program targetable by acetylation-related modifiers. High KANSL2 levels increased sensitivity to the histone deacetylase (HDAC) inhibitor panobinostat and bromodomain and extra-terminal motif (BET) inhibitor OTX-015 and their combination. Ex vivo drug response profiling revealed that high KANSL2 expression enhances sensitivity to HDAC and BET inhibitors in primary MM patient samples. Collectively, these findings position KANSL2 as a mediator of chemotherapy resistance and actionable biomarker for response to epigenetic regulators.

2026-02-22 | PXD066205 | Pride

The Role of Maternal Obesity in Offspring Cardiovascular Development and Congenital Heart Defects

Project description:Background: Congenital heart disease (CHD) is a leading cause of death in newborns, yet many of its molecular mechanisms remain unknown. Both maternal obesity and diabetes increase the risk of CHD in offspring, with recent studies suggesting these conditions may have distinct teratogenic mechanisms. The global prevalence of obesity is rising, and while maternal obesity is a known risk factor for fetal CHD, the specific mechanisms are largely unexplored. Methods: We used a murine model of diet-induced maternal obesity, without diabetes, to produce dams that were overweight but had normal blood glucose levels. Embryos were generated and their developing hearts analyzed. Transcriptome analysis was performed using single-nuclei (snRNAseq) and bulk RNA sequencing (RNA-seq). Global and phospho-enriched proteome analysis was performed using tandem-mass tag mass spectroscopy (TMT-MS). Immunobloting and histologic evaluation were also performed. Results: Analysis revealed disrupted oxidative phosphorylation and reactive oxygen species formation, with reduced antioxidant capacity, evidenced by downregulation of genes Sod1 and Gp4x, and disrupted Hif1a signaling. Evidence of oxidative stress, cell death signaling, and alteration in Rho GTPase and actin cytoskeleton signaling was also observed. Genes involved in cardiac morphogenesis, including Hand2, were downregulated, and fewer mature cardiomyocytes were present. Histologic analysis confirmed increased cardiac defects in embryos exposed to maternal obesity. Conclusion: These findings demonstrate maternal obesity alone can result in cardiac defects through mechanisms similar to those associated with maternal hyperglycemia. This study provides valuable insights into the role of maternal obesity, a growing and modifiable risk factor, in the development of the most common birth defect, CHD.

2025-06-30 | PXD062087 | Pride

High-Throughput Proteomics Sample Preparation Using 96-Channel Pipettor and Magnetic Pin Device

Project description:The advent of high-throughput proteomics has created an urgent need for parallel increases in sample processing productivity. However, workflows—particularly those involving PTM profiling—remain highly complex and consist of multiple steps that demand exceptional reproducibility. Many laboratories are transitioning to liquid-handling systems to automate parts of the workflow, but the transition from manual pipetting to full automation of phosphoproteomics can be technically demanding and cost-prohibitive. Here, we describe a practical intermediate solution: the use of a manually operated 96-channel pipettor (Platemaster P220) in combination with a 96-well magnetic pin device (MagPin, VP Scientific). Using these devices, we demonstrate highly efficient and reproducible execution of a complete phosphoproteomics workflow in 96-well format, involving PAC digestion, desalting, phosphoenrichment and second round of desalting within just two days, with low operator workload, minimal sample preparation variability and virtually no risk of error. As part of the workflow, we also present a methodology for producing affordable, highly reproducible Oasis HLB 96-well SPE plates by directly packing HLB sorbent material into tapered filter plates. We comprehensively characterise these custom Oasis HLB plates with respect to loading capacity, acetonitrile percentage required for peptide elution, lipid removal efficiency, and suitability for high-pH fractionation.

2026-02-17 | PXD069607 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data